KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Reply to Francesco Montorsi, Giuseppe Rosiello, Giorgio Gandaglia, Andrea Salonia, and Alberto Briganti's Letter to the Editor re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol 2023;6:508-15. PMID 37978025 · Eur Urol Oncol · 2024-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.07.010. PMID 37951819 · Eur Urol Oncol · 2024-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effect of a Home-based Walking Intervention on Cardiopulmonary Fitness and Quality of Life Among Men with Prostate Cancer on Active Surveillance: The Active Surveillance Exercise Randomized Controlled Trial. PMID 37907387 · Eur Urol Oncol · 2024-Jun Eligible criteria not met: intervention is exercise-only (no drug), and primary/secondary endpoints are not time-to-event efficacy measures (OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Digital Tracking of Patients Undergoing Radical Cystectomy for Bladder Cancer: Daily Step Counts Before and After Surgery Within the iROC Randomised Controlled Trial. PMID 37852921 · Eur Urol Oncol · 2024-Jun Study is an observational cohort within a randomized trial, focusing on wearable activity trackers (non-drug intervention) and step count outcomes, not time-to-event efficacy endpoints like OS or PFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Magnetic Resonance Imaging-Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE). PMID 37838556 · Eur Urol Oncol · 2024-Jun The study is an oncology RCT but fails two key eligibility criteria: it is not a drug intervention trial and its primary endpoint is not a time-to-event efficacy measure.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study. PMID 37838555 · Eur Urol Oncol · 2024-Jun The record describes a prospective cohort study (non-randomized) assessing biomarker prognostic value for a drug already in use. It does not meet the core criteria of being a randomized trial with a drug-containing intervention compared to control.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. PMID 37821242 · Eur Urol Oncol · 2024-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Surgery with or Without Darolutamide in High-risk and/or Locally Advanced Prostate Cancer: The SUGAR (CCAFU-PR2) Phase 2 Trial Rationale and Protocol. PMID 37806843 · Eur Urol Oncol · 2024-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Interventional radiology meets immuno-oncology for hepatocellular carcinoma. PMID 35988688 · J Hepatol · 2024-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effects of a Resistance Exercise Program in Patients with Colorectal Cancer Undergoing Chemotherapy Treatment: A Randomized Controlled Trial Study Protocol. PMID 39124745 · J Clin Med · 2024-Jul-31 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Antihypertensive treatment for kidney transplant recipients. PMID 39082471 · Cochrane Database Syst Rev · 2024-Jul-31 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy of Traditional Chinese Medicine Combined Online Group Psychotherapy (TCM-eRhab) on improving quality of life and relieving psychological burden for colorectal cancer survivors: a study protocol for a phase-II randomized controlled trial. PMID 39080684 · BMC Complement Med Ther · 2024-Jul-30 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer. PMID 39080281 · NPJ Breast Cancer · 2024-Jul-30 The trial is an oncology randomized study in humans with a drug intervention and reports time-to-event (OS) outcomes. However, the trial phase is not explicitly stated in the provided information as Phase III/IIIb or Phase II/III, which is a strict requirement for eligibility. Additionally, the abstract identifies OS as a secondary endpoint, which may not satisfy the 'primary/key secondary' criterion if OS was not designated as such for this specific publication.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy of vitamin C on chemotherapy-related anemia in pancreatic cancer: study protocol for a randomized controlled trial. PMID 39075587 · Trials · 2024-Jul-29 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Postoperative radiotherapy with docetaxel versus cisplatin for high-risk oral squamous cell carcinoma: a randomized phase II trial with exploratory analysis of ITGB1 as a potential predictive biomarker. PMID 39075531 · BMC Med · 2024-Jul-29 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Increasing Colorectal Screening Uptake in Spouses of Patients With Colorectal Cancer Using a Randomized Behavioral Trial. PMID 39074504 · J Natl Compr Canc Netw · 2024-Jul-29 This is a randomized trial in oncology (colorectal cancer) but evaluates a behavioral intervention to increase screening uptake in spouses of patients, not a drug-containing intervention for treating patients with cancer. The primary endpoint is screening uptake (proportion), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, etc.) for a cancer treatment. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214. PMID 39060019 · J Immunother Cancer · 2024-Jul-25 The record explicitly reports original results from a Phase III randomized trial (CheckMate 214) evaluating drug interventions in human oncology, with primary/key secondary time-to-event efficacy endpoints (OS, TFS). The 5-year update qualifies as an original result report.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 1 Figure · 4 Panel · risk unclear
FOUND Trial: randomised controlled trial study protocol for case finding of obstructive sleep apnoea in primary care using a novel device. PMID 39059802 · BMJ Open · 2024-Jul-25 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study. PMID 39054476 · BMC Cancer · 2024-Jul-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study. PMID 39054467 · BMC Cancer · 2024-Jul-25 The record describes a phase 3 randomized trial with drug interventions and is an original primary result report. However, the primary endpoint was objective response rate (ORR), a response-based measure, not a time-to-event endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP). The abstract does not mention Kaplan-Meier survival analysis, hazard ratios, or any other time-to-event efficacy results. Therefore, it fails the 'time_to_event' criterion, which is required for inclusion in this digitization cohort focused on Kaplan-Meier data.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Recurrence-free survival after curative resection of non-small cell lung cancer between inhalational gas anesthesia and propofol-based total intravenous anesthesia: a multicenter, randomized, clinical trial (GAS TIVA trial): protocol description. PMID 39039548 · Perioper Med (Lond) · 2024-Jul-23 The record is a protocol for a randomized trial in oncology humans with a time-to-event primary endpoint (RFS). However, it is excluded because: 1) It is a protocol without results, not an original result report; 2) The intervention (anesthetic technique) is not a drug-containing cancer intervention (e.g., chemotherapy); 3) The phase is not explicitly stated as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16. PMID 38739707 · Blood Adv · 2024-Jul-23 The record describes a randomized trial in human multiple myeloma patients with a drug intervention (daratumumab + VCD vs VCD) and reports primary PFS endpoint with KM estimates and HR. While the phase is not explicitly stated as 'Phase III' in the abstract, the trial design (large randomized trial with standard-of-care comparator, multi-center registration) and context (myeloma treatment development) strongly suggest definitive Phase III/IIIb evidence. All other eligibility criteria are met.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 2 Figure · 2 Panel · risk visible
ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer. PMID 39039449 · BMC Cancer · 2024-Jul-22 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The effect of tinzaparin on biomarkers in FIGO stages III-IV ovarian cancer patients undergoing neoadjuvant chemotherapy - the TABANETOC trial: study protocol for a randomized clinical multicenter trial. PMID 39037076 · Acta Oncol · 2024-Jul-22 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study. PMID 38776484 · J Clin Oncol · 2024-Jul-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116). PMID 38709986 · J Clin Oncol · 2024-Jul-20 The study is an original, human, oncology, Phase III randomized trial with a drug intervention, but it does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) or report Kaplan-Meier or HR analysis for such an endpoint. The primary outcome is a cognitive test score, which is not a time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Elective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients With Unfavorable-Risk Prostate Cancer: A Postrandomization Analysis. PMID 38691823 · J Clin Oncol · 2024-Jul-20 The record is a secondary, subgroup, or postrandomization analysis of a randomized trial. It does not present the primary or key secondary efficacy result of the overall trial. The phase is not explicitly established in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Correction: PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer patients (PETNECK2): study protocol for a multicentre feasibility study and non-inferiority, randomised, phase III trial. PMID 39026293 · BMC Cancer · 2024-Jul-18 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A protocol for a multidisciplinary early intervention during chemotherapy to improve dietary management behavior in breast cancer patients: a two-arm, single-center randomized controlled trial. PMID 39026219 · BMC Cancer · 2024-Jul-18 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Combination of neoadjuvant and adjuvant chemotherapy with FOLFOX compared with adjuvant chemotherapy in management of locally advanced rectal cancers: a randomized trial of a promising therapeutic approach. PMID 39026218 · BMC Cancer · 2024-Jul-18 The record is an original report of a randomized trial in human oncology with a drug-containing intervention and a primary time-to-event efficacy endpoint (DFS). However, the trial phase is not explicitly stated in the provided metadata (title, abstract, publication types, MeSH, keywords, or registration). The deterministic review also flagged 'phase3_evidence_unclear' as the reason for needing review. Without explicit confirmation of Phase III/IIIb or Phase II/III status, the required criterion 'phase3_or_definitive' cannot be established, making the record ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease. PMID 39018531 · N Engl J Med · 2024-Jul-18 The study is a randomized, Phase 3b trial of drug interventions (risankizumab vs. ustekinumab) with original results, but it is not in oncology. It investigates Crohn's disease (inflammatory bowel disease), not human malignant neoplasm. Furthermore, the primary and secondary endpoints (clinical remission, endoscopic remission) are not time-to-event efficacy endpoints (e.g., OS, PFS, DFS).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma. PMID 38669626 · Blood · 2024-Jul-18 The record describes a propensity score-matched comparison of two treatment groups from the LyMa-101 trial, which appears to be a single-arm trial (obinutuzumab-based) with an external comparator group (rituximab-based). While randomized, the phase of the trial is not explicitly stated as Phase III/IIIb or Phase II/III. The analysis is a secondary comparison, not the primary report of a randomized Phase III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): study protocol for an adaptive randomised controlled clinical trial. PMID 39020446 · Trials · 2024-Jul-17 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The role of vitamin D in amelioration of oral lichen planus and its effect on salivary and tissue IFN-γ level: a randomized clinical trial. PMID 39020381 · BMC Oral Health · 2024-Jul-17 The study is a randomized trial of vitamin D adjunct to steroids for oral lichen planus (an oral potentially malignant disease), but it does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The primary outcomes are clinical scores, pain relief, and cytokine levels measured at a fixed time point, not Kaplan-Meier or hazard ratio analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Differential effects of desvenlafaxine on hot flashes in women with breast cancer taking tamoxifen: a randomized controlled trial. PMID 39019875 · NPJ Breast Cancer · 2024-Jul-17 The record describes a randomized Phase 3 trial with a drug intervention (desvenlafaxine) in oncology patients. However, the study's primary endpoint is the change rate in hot flash scores, a symptom/quality-of-life measure, not a time-to-event efficacy endpoint like OS, PFS, or DFS. Therefore, it does not meet the cohort's requirement for a primary/key secondary time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of patient-based self-assessed fatigue intervention on early postoperative ambulation following gynaecological oncology surgery: a randomised controlled non-inferiority trial. PMID 39019626 · BMJ Open · 2024-Jul-17 The study is a randomized trial in gynecologic oncology patients, but the intervention is a non-drug (nursing/patient self-assessment) strategy, and the primary outcome is time to first flatus, which is not an oncologic time-to-event efficacy endpoint (e.g., OS, PFS, DFS). No drug intervention or relevant Phase III/IIIb or Phase II/III drug trial is described.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Recruitment strategies and consent rates in a national prospective colorectal cancer screening cohort: results from year 1 of the Voyage Study. PMID 39019622 · BMJ Open Gastroenterol · 2024-Jul-17 The record describes a randomized trial within a prospective cohort study focused on optimizing recruitment strategies (incentives) for colorectal cancer screening. It is not a Phase III/IIIb or Phase II/III trial of a drug-containing intervention for treatment. The primary endpoint is consent/participation rate, not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. Therefore, it does not meet the core criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma. PMID 39013886 · Nat Commun · 2024-Jul-16 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial. PMID 39013870 · Nat Commun · 2024-Jul-16 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer. PMID 38630755 · Clin Cancer Res · 2024-Jul-15 The study analyzes biomarkers from two single-arm Phase IIIb trials, not the primary efficacy results of a randomized trial. While it has human, oncology, phase III, time-to-event, and drug intervention characteristics, it is not a randomized trial and is a secondary analysis focused on transcriptomic subtyping and biomarkers, not the original trial efficacy report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Electronic health intervention to manage symptoms of immunotherapy in patients with cancer (SOFIA): Results from a randomized controlled pilot trial. PMID 38564338 · Cancer · 2024-Jul-15 The study is a randomized, human, oncology trial with a drug intervention (immune checkpoint inhibitors). However, it is a pilot trial focused on feasibility and quality-of-life outcomes, not a definitive Phase III/IIIb trial. Most critically, it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The abstract notes that survival data were examined but showed no significant differences, but survival is not the primary or key efficacy endpoint and the specific time-to-event analysis method (e.g., KM, HR) is not reported.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Baseline breast tissue characteristics determine the effect of tamoxifen on mammographic density change. PMID 38554131 · Int J Cancer · 2024-Jul-15 The study is a randomized, placebo-controlled trial within an oncology context (breast cancer prevention) with a drug intervention (tamoxifen). However, it is not a Phase III/IIIb trial (phase is not specified but the nested design and small sample size suggest it is not a definitive efficacy trial). The primary endpoint is mammographic density change (a biomarker/imaging endpoint), not a clinical time-to-event efficacy endpoint such as OS, PFS, DFS, etc. The report focuses on associations between baseline tissue features and the density change, which is a biomarker analysis, not a direct report of survival or recurrence outcomes from the parent trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Five-Year Mortality Outcomes for Eating As Treatment (EAT), a Health Behavior Change Intervention to Improve Nutrition in Patients With Head and Neck Cancer: A Stepped-Wedge, Randomized Controlled Trial. PMID 38320712 · Int J Radiat Oncol Biol Phys · 2024-Jul-15 The study is an oncology randomized controlled trial with a time-to-event efficacy endpoint (5-year mortality, HR 0.39) and original results. However, it does not involve a drug-containing intervention (the EAT intervention is behavioral/nutritional, delivered by dietitians, with no drug component), and the trial phase is not explicitly stated in the provided metadata to be Phase III/IIIb or Phase II/III. Therefore, it does not meet all required criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prospective Randomized Phase 2 Trial of Hypofractionated Stereotactic Radiation Therapy of 25 Gy in 5 Fractions Compared With 35 Gy in 5 Fractions in the Reirradiation of Recurrent Glioblastoma. PMID 38232937 · Int J Radiat Oncol Biol Phys · 2024-Jul-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Urethra-Sparing Prostate Cancer Stereotactic Body Radiation Therapy: Sexual Function and Radiation Dose to the Penile Bulb, the Crura, and the Internal Pudendal Arteries From a Randomized Phase 2 Trial. PMID 38160915 · Int J Radiat Oncol Biol Phys · 2024-Jul-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effectiveness of post-COVID-19 primary care attendance in improving survival in very old patients with multimorbidity: a territory-wide target trial emulation. PMID 39004436 · Fam Med Community Health · 2024-Jul-14 The study is a non-oncology, non-drug, non-randomized retrospective cohort analysis of primary care attendance after COVID-19 hospitalization. It does not meet the criteria for an oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Does metformin really reduce prostate cancer risk: an up-to-date comprehensive genome-wide analysis. PMID 38997745 · Diabetol Metab Syndr · 2024-Jul-12 This is a Mendelian randomization (observational) study investigating the genetic association between predicted metformin use and prostate cancer risk. It is not a clinical trial, does not randomize patients, does not report a time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier curves or hazard ratios, and does not test a drug intervention in a controlled trial setting.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The impact of Paclitaxel-based hyperthermic intraperitoneal chemotherapy in advanced high-grade serous ovarian cancer patients - interim analysis of safety and immediate efficacy of a randomized control trial (C-HOC trial). PMID 38997720 · J Ovarian Res · 2024-Jul-12 This is an interim analysis of a randomized controlled trial focusing on safety, feasibility, and a surrogate endpoint (chemotherapy response score). It does not report on the primary or key secondary time-to-event efficacy endpoints (OS, PFS, etc.) required for inclusion in a Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension. PMID 38992025 · Pharmacogenomics J · 2024-Jul-12 The record is an oncology Phase III randomized trial evaluating a drug (bevacizumab). However, the study's primary analysis is a biomarker/risk-prediction analysis for a toxicity endpoint (bevacizumab-induced hypertension), not a time-to-event efficacy endpoint like OS, PFS, or DFS. No Kaplan-Meier curves, hazard ratios for efficacy, or time-to-event data are reported in the abstract. It is excluded because it lacks the required primary/key secondary time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Carvedilol to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by liver stiffness: study protocol for a randomied, double-blind, placebo-controlled, multicentre trial in China. PMID 38991669 · BMJ Open · 2024-Jul-11 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -